Medicure’s Only Risk

Medicure (TSXV: MPH)’s only risk is that FDA Priority Review Vouchers decline in value. Last week, the latest transaction for a Priority Review Voucher took place when Egetis Therapeutics sold one for US$190 million (click here to see).

However, this would only become a risk for MPH once its market cap surpasses US$150 million+ in the upcoming months. As long as you enter MPH early near its current market cap of US$27.71 million there pretty much is no risk.

Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA’s President has purchased 87,000 shares of MPH and intends to buy more shares. This message is meant for informational and educational purposes only.